Skip to main content
Clinical Trials/NCT04186832
NCT04186832
Active, not recruiting
Not Applicable

Feasibility of Monitoring Step Count as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Patients Undergoing Radiation Therapy

M.D. Anderson Cancer Center1 site in 1 country50 target enrollmentSeptember 28, 2020

Overview

Phase
Not Applicable
Intervention
Pedometer
Conditions
Glioma
Sponsor
M.D. Anderson Cancer Center
Enrollment
50
Locations
1
Primary Endpoint
Satisfaction/acceptability rate questionnaire
Status
Active, not recruiting
Last Updated
2 months ago

Overview

Brief Summary

This trial studies the feasibility of monitoring step count as a measure of physical activity in patients with newly diagnosed glioma undergoing radiation therapy. Physical activity measured by step count may help to improve the quality of life and symptoms for patients with newly diagnosed glioma.

Detailed Description

PRIMARY OBJECTIVE: I. Evaluate the feasibility of monitoring step count as a measure of physical activity in patients with newly diagnosed glioma undergoing radiation therapy (RT) at MD Anderson Cancer Center (MDACC). SECONDARY OBJECTIVE: I. Estimate the effects of physical activity as measured by step count on cognition, fatigue, anxiety and depression scores and assess differences between groups. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients wear a pedometer for step count monitoring over 6 weeks. GROUP II: Patients wear a FitBit for step count monitoring over 6 weeks. After completion of study, patients are followed up at 3 and 6 months after completing radiation therapy.

Registry
clinicaltrials.gov
Start Date
September 28, 2020
End Date
December 31, 2027
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with a glioma and going to receive at least 4 weeks of RT at MDACC at the Texas Medical Center campus with at least 20 fractions
  • Karnofsky performance status (KPS) of 70 or above
  • Wearable activity tracker (WAT) - naive
  • Able to read and speak English
  • Able to provide informed consent
  • Access to a smartphone
  • Access to Wi-Fi

Exclusion Criteria

  • Cognitive and/or major sensory deficits that would impede the completion of assessment instruments as deemed by the clinical team

Arms & Interventions

Group I (pedometer)

Patients wear a pedometer for step count monitoring over 6 weeks.

Intervention: Pedometer

Group I (pedometer)

Patients wear a pedometer for step count monitoring over 6 weeks.

Intervention: Quality-of-Life Assessment

Group I (pedometer)

Patients wear a pedometer for step count monitoring over 6 weeks.

Intervention: Questionnaire Administration

Group II (FitBit)

Patients wear a FitBit for step count monitoring over 6 weeks.

Intervention: FitBit

Group II (FitBit)

Patients wear a FitBit for step count monitoring over 6 weeks.

Intervention: Quality-of-Life Assessment

Group II (FitBit)

Patients wear a FitBit for step count monitoring over 6 weeks.

Intervention: Questionnaire Administration

Outcomes

Primary Outcomes

Satisfaction/acceptability rate questionnaire

Time Frame: Up to 6 months

Will evaluate the satisfaction/acceptability rate in both FitBit and pedometer groups. Will calculate the rates, frequencies, and 90% CIs of the proportions by group and in total, as well as for the differences between intervention groups, as applicable.

Fitbit adherence rate

Time Frame: Up to 6 weeks

Feasibility will be assessed by treatment group (Fitbit) adherence rate. Intervention adherence is defined as wearing the Fitbit for a total of at least 340 hours across the 6-week intervention period. Will calculate the rates, frequencies, and 90% CIs of the proportions by group and in total, as well as for the differences between intervention groups, as applicable.

Consent rate

Time Frame: Up to 6 months after completing radiation therapy

Feasibility will be assessed by the consent rate. Will calculate the rates, frequencies, and 90% confidence intervals (CIs) of the proportions by group and in total, as well as for the differences between intervention groups, as applicable.

Retention rate

Time Frame: Up to 6 months

Feasibility will be assessed by the retention rate. Retention will be defined by the completion of assessments, by the end of the intervention (6 weeks from baseline) in each group. Will calculate the rates, frequencies, and 90% CIs of the proportions by group and in total, as well as for the differences between intervention groups, as applicable.

Study Sites (1)

Loading locations...

Similar Trials